Drug Combination Details
| General Information of the Combination (ID: C48702) | |||||
|---|---|---|---|---|---|
| Name | Alprostadil + Plasmin | + | Trimetazidine | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Alprostadil NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Plasmin NP Info | ||||
| Structure |
|
|
|||
| Disease |
Atherosclerosis
[ICD-11: BD40]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Experimental
Result(s) |
Trimetazidine and plasmin combined with alprostadil can effectively treat lower extremity arteriosclerosis obliterans. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. Exp Ther Med. 2019 Jun;17(6):4554-4560. | |||
